<DOC>
	<DOCNO>NCT02347098</DOCNO>
	<brief_summary>The purpose randomize , multi-site , clinical trial determine whether intensive therapy consist cholesterol-lowering statin drug plus apheresis cleanse blood low-density lipoprotein ( LDL ) cholesterol effective statin therapy alone reduce plaque volume heart arteries patient already suffer acute coronary syndrome ( ACS ) . The study also investigate whether intensive approach help increase presence endothelial progenitor cell ( EPC ) , stem cell show reduce CV event ACS patient . This study two phase FDA approval phase II receive information update reflect PREMIER Phase II .</brief_summary>
	<brief_title>Plaque Regression Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen ( PREMIER ) , Phase II</brief_title>
	<detailed_description>Using statin low blood cholesterol , specifically LDL , well establish long-term strategy reduce CVs even death . But intensive pharmacologic lipid-lowering therapy statin , though proven superior standard dose regimen , still associate unacceptably high rate recurrent CV event early ACS . This study hypothesize ACS patient undergo percutaneous coronary intervention ( PCI ) , intensive lipid-lowering therapy consist statin LDL-apheresis ( ILLT ) significantly reduce total coronary atheroma volume vulnerable plaque augment mobilization peripherally circulate EPC colony form unit , compare guideline statin monotherapy ( SMT ) . ILLT lead few CV event patient . Patients present four VA site ACS screen consent undergoing uncomplicated PCI ( balloon stent ) intravascular ultrasound virtual histology ( IVUS-HS ) . They randomize ILLT arm SMT arm study . The ILLT group receive one treatment LDL-apheresis plus daily oral 40- 80mg dose Atorvastatin equivalent statin ; SMT group get 40-80mg Atorvastatin equivalent . Patients undergo IVUS-HS 12 week enrollment measure atheroma volume ; EPC level also check . The three-year duration study include 24 month accrual , six month follow-up , 12 month study closure data analysis . A two-sample t-test mean difference 90 % power 0.65 Cohen 's D effect size provide total sample size estimate 102 . Counting 20 % drop-out rate , sample size increase 128 . The recent FDA recommendation regard design study include revise study protocol : 1 . The safety data submit FDA . 2 . Patients randomize LDL-apheresis oral daily dose 40-80mg Atorvastatin equivalent statin ( Intensive LDL-lowering therapy/ILLT ) daily dose 40-80mg Atorvastatin equivalent statin without LDL-apheresis ( standard statin monotherapy/SMT ) follow uncomplicated PCI .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Willing able provide inform consent ( include HIPAA ) Age &gt; 30 year Presenting acute coronary syndrome ( ACS ) , manifest unstable angina nonSTelevation myocardial infarction Referred clinicallyindicated , nonemergent ( procedure require perform within 3 hour patient presentation ) coronary angiography PCI IVUSVH target coronary artery ACS Successful placement two large bore IV cannulas bilateral upper extremity Fasting ( 12 hr . ) LDL 70mg/dl less equal 80mg Atorvastatin equivalent dose statin , perform time admission prior PCI . Known allergy aspirin , clopidogrel , statin , iodinate contrast Positive pregnancy test , plan become pregnant , breastfeed Coexisting condition limit life expectancy less six month affect patient compliance Uncontrolled fasting ( 12 hr . ) triglyceride level ( 500mg/dl ) Already participate investigational device drug study History heparin induce thrombocytopenia ( HIT ) Persons eGFR less 45 ml/min STelevation myocardial infarction admission Abnormal liver function test ( LFT ) time admission prior PCI abnormal LFT define liver transaminase ( ALT AST ) 3 time upper limit normal laboratory reference PrePCI postPCI leave ventricular ejection fraction &lt; 25 % echo cardiac catheterization do admission PrePCI , intraPCI , postPCI hemodynamic instability hypotension PrePCI , intraPCI , postPCI cardiac arrest PrePCI postPCI acute heart failure without pulmonary edema IntraPCI postPCI sustain ventricular tachycardia Complicated PCI , define PCI vascular access complication ( large hematoma lump &gt; 5 cm require medical treatment ; AV fistula ; pseudo aneurysm require treatment ; retroperitoneal bleeding ) , PCI procedural complication ( abrupt vessel closure ; noreflow phenomenon ; new angiographic thrombus ; new major dissection reduce flow ; catheterrelated thrombus ) , PCI require medical treatment ( urgent CABG ; endotracheal intubation ; unplanned inaortic balloon pump ; LVAD ; cover stent ; unplanned temporary pacemaker wire ; administration inotropes ; CPR ) , PCI result clinical event ( death ; stroke ; myocardial infarction ; stent thrombosis ) within 24 hour index PCI PostPCI ongoing chest pain PostPCI severe groin pain hematoma &gt; 5cm diameter Persons whose hemoglobin le 9 gram follow index PCI/IVUS procedure , experience drop hemoglobin great equal 2 gram follow procedure Not able comply study protocol determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>plaque</keyword>
	<keyword>LDL</keyword>
	<keyword>statin</keyword>
	<keyword>endothelial</keyword>
	<keyword>apheresis</keyword>
	<keyword>acute coronary artery syndrome</keyword>
</DOC>